Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15 17
Multi-Infarct Dementia 77 55 74
Dementia, Vascular 77 45 74
Vascular Dementia, Susceptibility to 6
Dementia, Multi-Infarct 45
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 56

Classifications:



External Ids:

Disease Ontology 12 DOID:8725
ICD9CM 36 290.4
SNOMED-CT 69 56267009
ICD10 34 F01 F01.1 F01.5

Summaries for Vascular Dementia

NINDS : 55 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic. 

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Selenium Micronutrient Network and Neuroscience. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 77 Vascular dementia, is dementia caused by problems in the supply of blood to the brain, typically a... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 32.0 ACHE APOE APP MAPT NOTCH3
2 dementia 31.4 ACHE APOE APP BCHE CHAT MAPT
3 alzheimer disease 30.8 ACHE APOE APP BCHE CHAT CST3
4 vascular disease 30.8 APOE CST3 MTHFR PON1 TNF VEGFA
5 atherosclerosis susceptibility 30.2 APOE PON1 TNF
6 carotid stenosis 30.2 APOE MTHFR TNF
7 frontotemporal dementia 30.1 ACHE APOE APP MAPT PSEN1
8 head injury 29.8 APOE CHAT
9 cerebrovascular disease 29.7 ACHE APOE APP MAPT MTHFR NOTCH3
10 hydrocephalus 29.7 APOE APP MAPT MBP
11 arteries, anomalies of 29.6 APOE PON1 TNF VEGFA
12 brain injury 29.5 APOE MAPT MBP
13 dementia, lewy body 29.4 ACHE APOE APP BCHE MAPT PSEN1
14 parkinson disease, late-onset 29.3 ACHE APOE APP CHAT MAPT
15 cerebral amyloid angiopathy, cst3-related 29.3 APOE APP CST3 MAPT PSEN1 SERPINA3
16 heart disease 29.2 APOE CST3 MTHFR PON1 TNF VEGFA
17 alzheimer disease 2 29.0 APOE APP BCHE MAPT PSEN1 SERPINA3
18 myocardial infarction 28.9 APOE CST3 MTHFR PON1 TNF VEGFA
19 subcortical arteriosclerotic encephalopathy 11.2
20 cerebral arteriosclerosis 11.2
21 dementia - subcortical 11.0
22 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.0
23 dementia pugilistica 10.5
24 simultanagnosia 10.4 APOE MAPT
25 posterior cortical atrophy 10.4 APOE MAPT
26 depression 10.4
27 aging 10.4
28 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 10.4
29 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.4
30 nominal aphasia 10.3 MAPT PSEN1
31 alzheimer's disease 1 10.3 APOE APP
32 alzheimer disease 4 10.3 APOE PSEN1
33 progressive non-fluent aphasia 10.3 MAPT PSEN1
34 butyrylcholinesterase deficiency 10.3 ACHE BCHE
35 behavioral variant of frontotemporal dementia 10.3 MAPT PSEN1
36 ischemic heart disease 10.3 APOE MTHFR TNF
37 cerebral atherosclerosis 10.3 APOE MTHFR
38 cerebral palsy 10.3 APOE MTHFR TNF
39 hemifacial spasm 10.3 MTHFR VEGFA
40 semantic dementia 10.2 APOE MAPT PSEN1
41 critical limb ischemia 10.2 TNF VEGFA
42 early-onset, autosomal dominant alzheimer disease 10.2 APP PSEN1
43 alzheimer disease mitochondrial 10.2 APOE APP MAPT
44 kashin-beck disease 10.2 TNF VEGFA
45 speech and communication disorders 10.2 APOE MAPT PSEN1
46 gait apraxia 10.2 APOE APP PSEN1
47 inclusion body myositis 10.2 APOE APP MAPT
48 hereditary cerebral amyloid angiopathy 10.2 APP CST3
49 senile plaque formation 10.2 APOE APP CHAT
50 ischemia 10.2

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACHE APOE APP BCHE CHAT CST3
2 behavior/neurological MP:0005386 10.33 ACHE APOE APP CHAT MAPT MBP
3 growth/size/body region MP:0005378 10.26 ACHE APOE APP CHAT MAPT MBP
4 mortality/aging MP:0010768 10.25 ACHE APOE APP BCHE CHAT CST3
5 cardiovascular system MP:0005385 10.24 APOE APP CHAT CST3 MAPT NOTCH3
6 nervous system MP:0003631 10.21 ACHE APOE APP CHAT CST3 MAPT
7 hematopoietic system MP:0005397 10.16 ACHE APOE APP MAPT MBP NOTCH3
8 integument MP:0010771 10.13 APOE APP MAPT MTHFR NOTCH3 PSEN1
9 muscle MP:0005369 10.1 ACHE APOE APP CHAT CST3 MAPT
10 limbs/digits/tail MP:0005371 9.93 APOE CHAT MTHFR PSEN1 TNF VEGFA
11 reproductive system MP:0005389 9.93 ACHE APOE APP BCHE CHAT CST3
12 no phenotypic analysis MP:0003012 9.87 ACHE APOE APP MAPT MTHFR TNF
13 normal MP:0002873 9.86 APP CHAT MAPT MBP NEFL NOTCH3
14 respiratory system MP:0005388 9.5 ACHE APOE CHAT NOTCH3 PSEN1 TNF
15 vision/eye MP:0005391 9.32 ACHE APOE CHAT MAPT MBP MTHFR

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 62-31-7, 51-61-6 681
3
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
4
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
5
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
9
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
10
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
11
Corticosterone Experimental Phase 4 50-22-6 5753
12 Antidepressive Agents Phase 4,Phase 3
13 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
15 Parasympatholytics Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Serotonin Uptake Inhibitors Phase 4
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2
19 Serotonin Agents Phase 4,Phase 3
20 Muscarinic Antagonists Phase 4
21 Antidepressive Agents, Second-Generation Phase 4
22 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Cholinergic Antagonists Phase 4
24 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
25 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
27 Excitatory Amino Acids Phase 4,Not Applicable
28 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
29 Calcium, Dietary Phase 4,Phase 2,Phase 3,Not Applicable
30 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
31 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
32 calcium channel blockers Phase 4,Phase 2,Phase 3,Not Applicable
33 Vasodilator Agents Phase 4,Phase 2,Phase 3,Not Applicable
34 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Nootropic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Phosphodiesterase Inhibitors Phase 4,Phase 2
37 Antipyretics Phase 4,Phase 2
38 Platelet Aggregation Inhibitors Phase 4,Phase 3,Not Applicable
39 Anti-Inflammatory Agents Phase 4
40 Analgesics, Non-Narcotic Phase 4,Phase 2
41 Bronchodilator Agents Phase 4
42 Phosphodiesterase 3 Inhibitors Phase 4
43 Cyclooxygenase Inhibitors Phase 4
44 Anti-Asthmatic Agents Phase 4
45 Respiratory System Agents Phase 4
46 Antirheumatic Agents Phase 4
47 Fibrinolytic Agents Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Analgesics Phase 4,Phase 2
50 Neuroprotective Agents Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
4 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
11 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
12 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
13 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
14 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
15 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
16 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
17 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
18 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
19 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
20 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
21 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
22 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule Recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
23 Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Recruiting NCT03721705 Phase 3
24 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
25 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
26 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
27 Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function Recruiting NCT03082014 Phase 3 Amlodipine;Losartan;Atenolol
28 MIND Diet Intervention and Cognitive Decline Active, not recruiting NCT02817074 Phase 3
29 Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Not yet recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
30 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
31 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
32 Safety Study of Dabigatran in CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
33 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
34 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
35 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
36 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
37 Oxidative Stress and Nutritional Supplementation Intervention Study Completed NCT01234506 Phase 2
38 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
39 The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment Completed NCT00103948 Phase 2 Aricept
40 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Recruiting NCT03230071 Phase 2 TMBCZG
41 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
42 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
43 BAC in Patient With Alzheimer's Disease or Vascular Dementia Not yet recruiting NCT02467413 Phase 2 BAC
44 Aricept to Improve Functional Tasks in Vascular Dementia Active, not recruiting NCT00457769 Phase 1 Donepezil and self-generated memory training;Donepezil and experimenter-administered memory training
45 Managing Vascular Dementia Risk Factors With SymTrend Not yet recruiting NCT03702543 Phase 1
46 Remote Ischemic Preconditioning for Subcortical Vascular Dementia Unknown status NCT03022149 Not Applicable
47 Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study Unknown status NCT02018913
48 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330 Not Applicable
49 MRS and DTI of White Matter in Alzheimer's Disease Unknown status NCT00172900
50 Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie) Unknown status NCT01126775

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

42
Brain, Testes, Cortex, Endothelial, Temporal Lobe, Eye, Skin

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 2007)
# Title Authors Year
1
Anxiety as a risk factor of Alzheimer's disease and vascular dementia - ERRATUM. ( 30334505 )
2019
2
Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. ( 31056343 )
2019
3
Meta-Analysis on the Efficacy and Safety of Hyperbaric Oxygen as Adjunctive Therapy for Vascular Dementia. ( 31057392 )
2019
4
Dynamic Evaluation Indices in Spatial Learning and Memory of Rat Vascular Dementia in the Morris Water Maze. ( 31076665 )
2019
5
Glycogen synthase kinase-3 inhibition as a potential pharmacological target for vascular dementia: In silico and in vivo evidence. ( 31022582 )
2019
6
Involvement of Endothelin-1, H2S and Nrf2 in Beneficial Effects of Remote Ischemic Preconditioning in Global Cerebral Ischemia-Induced Vascular Dementia in Mice. ( 31025223 )
2019
7
Are neuropsychiatric symptoms modifiable risk factors for cognitive decline in Alzheimer's disease and vascular dementia? ( 31036096 )
2019
8
Effects of α-lipoic acid on chronic cerebrovascular hypoperfusion in an animal model of vascular dementia. ( 30964187 )
2019
9
A mouse model to investigate the effects of lifestyle on vascular dementia and Alzheimer's disease? ( 30980949 )
2019
10
Susceptibility Weighted Imaging (SWI) Recommended as a Regular Magnetic Resonance Diagnosis for Vascular Dementia to Identify Independent Idiopathic Normal Pressure Hydrocephalus Before Ventriculo-Peritoneal (V-P) Shunt Treatment: A Case Study. ( 30984097 )
2019
11
X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia. ( 30990878 )
2019
12
Peri-Infarct Upregulation of the Oxytocin Receptor in Vascular Dementia. ( 30990880 )
2019
13
Neuroprotective Effects of Zafirlukast, Piracetam and Their Combination on L-Methionine-Induced Vascular Dementia in Rats. ( 31001898 )
2019
14
Corrigendum to "FoxO1-mediated autophagy plays an important role in the neuroprotective effects of hydrogen in a rat model of vascular dementia" [Behav. Brain Res. 356 (2019) 98-106]. ( 31005352 )
2019
15
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. ( 30916555 )
2019
16
EEG Analysis and Spect Imaging in Alzheimer's Disease, Vascular Dementia and Mild Cognitive Impairment. ( 30948698 )
2019
17
A cortical microvascular structure in vascular dementia, Alzheimer's disease, frontotemporal lobar degeneration and nondemented controls: a sign of angiogenesis due to brain ischaemia? ( 30957900 )
2019
18
Association of Chronic Periodontitis on Alzheimer's Disease or Vascular Dementia. ( 30874308 )
2019
19
Emerging molecular mechanisms of vascular dementia. ( 30883434 )
2019
20
Naomaitai Ameliorated Brain Damage in Rats with Vascular Dementia by PI3K/PDK1/AKT Signaling Pathway. ( 30867669 )
2019
21
Glycyrrhizic acid renders robust neuroprotection in rodent model of vascular dementia by controlling oxidative stress and curtailing cytochrome-c release. ( 30794076 )
2019
22
Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the Aβ deposition. ( 30799178 )
2019
23
N-homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer's disease and vascular dementia. ( 30734924 )
2019
24
COWAT Performance of Persons with Alzheimer Dementia, Vascular Dementia, and Parkinson Disease Dementia According to Stage of Cognitive Impairment. ( 30746867 )
2019
25
Ameliorative effect of Phosphodiesterase-5 inhibitor in Rat model of Vascular Dementia. ( 30706814 )
2019
26
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes. ( 30721761 )
2019
27
Chotosan ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia via activating the Nrf2-mediated antioxidant pathway. ( 30642751 )
2019
28
N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. ( 30660740 )
2019
29
Hwangryunhaedok-Tang Exerts Neuropreventive Effect on Memory Impairment by Reducing Cholinergic System Dysfunction and Inflammatory Response in a Vascular Dementia Rat Model. ( 30669383 )
2019
30
Association of hyperglycemia episodes on long-term mortality in type 2 diabetes mellitus with vascular dementia: A population-based cohort study. ( 30420126 )
2019
31
CZ-7, a new derivative of Claulansine F, ameliorates 2VO-induced vascular dementia in rats through a Nrf2-mediated antioxidant responses. ( 30382185 )
2019
32
FoxO1-mediated autophagy plays an important role in the neuroprotective effects of hydrogen in a rat model of vascular dementia. ( 29885845 )
2019
33
A mouse model of subcortical vascular dementia reflecting degeneration of cerebral white matter and microcirculation. ( 29053032 )
2019
34
Memory for Serial Order in Alzheimer's Disease and Vascular Dementia: A Competitive Queuing Analysis. ( 29566139 )
2019
35
Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: a neuropathological study. ( 30509027 )
2018
36
Inhibitory Control, Task/Rule Switching, and Cognitive Planning in Vascular Dementia: Are There Any Differences From Vascular Aging? ( 30410439 )
2018
37
An Estimate of Attributable Cases of Alzheimer Disease and Vascular Dementia due to Modifiable Risk Factors: The Impact of Primary Prevention in Europe and in Italy. ( 29606955 )
2018
38
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
2018
39
Anxiety as a risk factor of Alzheimer's disease and vascular dementia. ( 30339108 )
2018
40
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
2018
41
The Prophylactic and Therapeutic Effects of Fermented Cordyceps sinensis Powder, Cs-C-Q80, on Subcortical Ischemic Vascular Dementia in Mice. ( 30662512 )
2018
42
Sildenafil treatment of vascular dementia in aged rats. ( 30592970 )
2018
43
Resveratrol prevents cognitive deficits by attenuating oxidative damage and inflammation in rat model of streptozotocin diabetes induced vascular dementia. ( 30550811 )
2018
44
Fastigial nucleus stimulation ameliorates cognitive impairment via modulating autophagy and inflammasomes activation in a rat model of vascular dementia. ( 30552710 )
2018
45
Efficacy and safety of Tianmabianchunzhigan in mild to moderate vascular dementia: Protocol of a randomized controlled IIa trial. ( 30572524 )
2018
46
Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. ( 30505270 )
2018
47
Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular dementia, and Mixed Dementia: Prevalence and Presentation. ( 30507582 )
2018
48
Traditional Chinese herbal medicine for vascular dementia. ( 30520514 )
2018
49
Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats. ( 30472896 )
2018
50
Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease. ( 30475760 )
2018

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh37 Chromosome 6, 31542482: 31542482
2 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh38 Chromosome 6, 31574705: 31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.85 APP MAPT NEFL PSEN1
2 endoplasmic reticulum lumen GO:0005788 9.83 APOE APP BCHE CST3
3 extracellular space GO:0005615 9.81 ACHE APOE APP BCHE CST3 PON1
4 membrane raft GO:0045121 9.8 APP MAPT PSEN1 TNF
5 neuron projection GO:0043005 9.8 APP CHAT MAPT NEFL PSEN1
6 cell surface GO:0009986 9.8 ACHE APP MBP PSEN1 TNF VEGFA
7 blood microparticle GO:0072562 9.67 APOE BCHE PON1 SERPINA3
8 platelet alpha granule lumen GO:0031093 9.63 APP SERPINA3 VEGFA
9 growth cone GO:0030426 9.56 APP MAPT NEFL PSEN1
10 synaptic cleft GO:0043083 9.54 ACHE APOE
11 ciliary rootlet GO:0035253 9.51 APP PSEN1
12 nuclear envelope lumen GO:0005641 9.48 APP BCHE
13 main axon GO:0044304 9.43 APP MAPT
14 extracellular region GO:0005576 9.36 ACHE APOE APP BCHE CST3 MAPT
15 neuromuscular junction GO:0031594 9.26 ACHE APP NEFL PSEN1

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 APOE APP CST3 PSEN1
2 response to oxidative stress GO:0006979 9.84 APOE APP PSEN1
3 platelet degranulation GO:0002576 9.83 APP SERPINA3 VEGFA
4 negative regulation of peptidase activity GO:0010466 9.83 APP CST3 SERPINA3
5 Notch signaling pathway GO:0007219 9.83 APP NOTCH3 PSEN1
6 positive regulation of protein phosphorylation GO:0001934 9.81 APP PSEN1 TNF VEGFA
7 response to toxic substance GO:0009636 9.8 MBP NEFL PON1
8 cholesterol metabolic process GO:0008203 9.79 APOE APP PON1
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 APP TNF VEGFA
10 forebrain development GO:0030900 9.75 APP NOTCH3 PSEN1
11 negative regulation of neuron apoptotic process GO:0043524 9.73 APOE NEFL PSEN1 RETREG1
12 negative regulation of gene expression GO:0010629 9.72 APOE APP MAPT TNF VEGFA
13 positive regulation of MAP kinase activity GO:0043406 9.7 PSEN1 TNF VEGFA
14 response to lead ion GO:0010288 9.67 APP MAPT
15 microglial cell activation GO:0001774 9.66 MAPT TNF
16 axon development GO:0061564 9.65 MAPT NEFL
17 synapse organization GO:0050808 9.65 APP MAPT PSEN1
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 APOE TNF
19 positive regulation of cholesterol efflux GO:0010875 9.64 APOE PON1
20 neurotransmitter biosynthetic process GO:0042136 9.63 ACHE CHAT
21 supramolecular fiber organization GO:0097435 9.62 CST3 MAPT
22 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APOE APP
23 neuron projection maintenance GO:1990535 9.6 APP PSEN1
24 amyloid fibril formation GO:1990000 9.59 APP MAPT
25 axonal transport of mitochondrion GO:0019896 9.58 MAPT NEFL
26 locomotion GO:0040011 9.57 NEFL PSEN1
27 response to folic acid GO:0051593 9.56 BCHE MTHFR
28 modulation of age-related behavioral decline GO:0090647 9.54 APP PSEN1
29 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.49 APP PSEN1
30 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.46 APP PSEN1
31 artery morphogenesis GO:0048844 9.43 APOE NOTCH3 VEGFA
32 astrocyte activation involved in immune response GO:0002265 9.4 APP PSEN1
33 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 APP PSEN1
34 amyloid precursor protein metabolic process GO:0042982 9.33 ACHE APOE PSEN1
35 positive regulation of amyloid fibril formation GO:1905908 9.13 APOE APP PSEN1
36 astrocyte activation GO:0048143 8.92 APP MAPT PSEN1 TNF

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 APP BCHE MAPT NOTCH3
2 peptidase inhibitor activity GO:0030414 9.58 APP CST3 SERPINA3
3 protease binding GO:0002020 9.54 CST3 MBP TNF
4 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
5 identical protein binding GO:0042802 9.28 APOE APP BCHE CST3 MAPT NEFL
6 cholinesterase activity GO:0004104 9.26 ACHE BCHE
7 amyloid-beta binding GO:0001540 9.26 ACHE APOE BCHE CST3
8 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....